Rivoceranib for locally advanced or metastatic gastric or gastro-oesophageal junction cancer – after two or more therapies
Rivoceranib is in clinical development for locally advanced, unresectable or metastatic gastric or gastro-oesophageal junction cancer that has progressed since last treatment with at least two prior lines of therapies. Gastric cancer is cancer that starts anywhere in the stomach. Cancer that starts between the oesophagus (food pipe) and the stomach is gastro-oesophageal junction cancer. Locally advanced cancer means that the cancer has spread into the tissues around the stomach. Advanced or metastatic means where the cancer has spread to another part of the body such as the liver or lungs. Advanced cancers have a poor prognosis and often have no cure, but treatment may control the cancer, relieve symptoms and give the patient a good quality of life.
Rivoceranib is an oral medicine with potential anti-tumour activities. It works by binding to a receptor responsible for preventing cell movement and multiplication and decrease the tumour mass. If licensed, rivoceranib will provide an additional treatment option for patients with locally advanced, unresectable or metastatic gastric or gastrooesophageal junction cancer that has progressed since last treatment with at least two prior lines of therapies.